Market Overview - The market showed signs of recovery after hitting a low, with the Shanghai Composite Index slightly down by 0.07% and the ChiNext Index briefly turning positive at the close [1] - The total trading volume in the Shanghai and Shenzhen markets was 1.95 trillion, a decrease of 486 billion compared to the previous trading day [5] Index Performance - Shanghai Composite Index closed at 4000.14, down 0.07% with 716 gainers and 1553 losers [2] - Shenzhen Component Index closed at 13240.62, down 0.36% with 934 gainers and 1901 losers [2] - ChiNext Index closed at 3122.03, down 0.39% with 448 gainers and 923 losers [2] Sector Performance - Defensive sectors showed strength, with oil and gas concepts surging, leading to stocks like PetroChina and Zhenhua Oil hitting the daily limit [2] - The pharmaceutical sector continued to rise, particularly in cell immunotherapy, with stocks like Kaineng Health and Jimin Health also hitting the daily limit [2] - The banking sector performed strongly, with Agricultural Bank of China and Industrial and Commercial Bank of China reaching historical highs [2] - Consumer stocks were active, with companies like Sanyuan and Zhongrui achieving consecutive gains [2] - The lithium battery sector saw a late rally, with Tianji shares performing well [2] - In contrast, superhard material stocks experienced significant declines, with World falling over 10% [2][3] Market Sentiment - Overall, more than 3500 stocks in the market declined, indicating a broad-based sell-off [2] - The market had a high limit-up rate of 75%, with 58 stocks hitting the limit and 19 stocks touching the limit-down [6]

（文章来源：每日经济新闻） 每经AI快讯，11月12日，创新药概念持续活跃，众生药业涨停，济民健康、南京新百、中源协和、盘 龙药业此前封板，三元基因、冠昊生物、热景生物、三生国健、亚太药业、百济神州-U等跟涨。 ...

该机构表示，内需CRO短期因此前行业需求低景气及订单价格下行的压力，各公司收入增速及毛利率 均承压。预期BD资金和二级热度上涨将反哺国内新药研发需求起量以及一级创新药项目融资活跃度提 升，内需CRO有望受益，预期在2026年看到订单端明显修复，并期待在2026年下半年看到财报端的兑 现，后续需关注国内需求景气度上行拐点以及头部CXO公司订单边际变化。 2025年起美联储进入降息周期，优质资产吸引资金重新布局，市场流动性有所改善；国产新药临床数据 超预期读出、重磅对外授权持续达成，行业估值水位随之提升。普涨行情后，创新药行业在2026年可能 会迎来结构性分化，动因来自基本面实质性进展，差异化竞争力进一步显现。获得MNC背书、具有 blockbuster潜力、全球竞争身位靠前、成药概率高的品种更有望带来超额收益。 创新药概念12日盘中强势上扬，截至发稿，三元基因涨超12%，济民健康、盘龙药业、中源协和等涨 停，冠昊生物、热景生物涨超7%，百济神州等涨超5%。 中金近日指出，2025年国产创新药批量读出具国际竞争力的临床数据，并发表于ASCO、ESMO等学术 大会或国际医学期刊。高质量研究充分展示了我国医药高水平创 ...

Group 1 - The immunotherapy sector is experiencing a strong rebound, with companies like Zhongyuan Qihuo and Kaineng Health hitting the daily limit up [1] - Other companies in the sector, such as Jimin Health, Guanhao Bio, Chengda Pharmaceutical, Zexing Pharmaceutical, and Heyuan Bio, are also showing significant gains [1]

Market Overview - The A-share market experienced slight fluctuations, with the Shanghai Composite Index consolidating around the 4000-point mark, while the ChiNext Index, Shenzhen Component Index, North 50, and Sci-Tech 50 all fell over 1% [1] - Over 4000 stocks declined, with trading volume remaining stable [1] Sector Performance - The pharmaceutical, oil and petrochemical, insurance, and banking sectors showed strong performance, while sectors such as photovoltaic equipment, cultivated diamonds, superconducting concepts, and ground weaponry faced declines [1] - The oil sector saw a significant rise, with the oil service engineering sector performing particularly well, reaching a new high for the year [6] Pharmaceutical Sector - The pharmaceutical stocks strengthened in the morning, with the pharmaceutical commercial sector leading the gains, reaching a new high for the year [3] - Notable stocks included Yao Yigou, which hit a 20% limit up shortly after opening, and He Fu China, which achieved 11 limit ups in nearly 12 trading days [3] Flu Season Impact - The flu season is expected to drive demand for pharmaceuticals, with the current flu activity at a moderate level across various provinces [5] - The upcoming flu season is anticipated to peak in late December and early January, with a focus on the H3N2 subtype [5] - The strategic significance of flu prevention and treatment is highlighted, with potential growth in vaccine development, infection control, and antiviral drug sectors [5] Oil Sector Highlights - The oil industry chain saw a comprehensive rise, with significant trading volume and a nearly 4% increase in the sector index [6] - Major companies like Jun Oil and Sinopec Oilfield Services reached their daily limit up shortly after market opening [6] - The Hong Kong oil sector also followed suit, with the Hang Seng Mainland Oil Index rising over 2%, marking a new high since February 2013 [8] Financial Performance - In the third quarter, 17 listed oil service companies reported a total revenue of 186.3 billion yuan, a year-on-year increase of 4.03%, and a net profit of 8.416 billion yuan, up 6.29% [8] - The Longqing Oilfield announced a cumulative shale oil production exceeding 20 million tons, indicating a new phase in large-scale development [8]

Group 1 - The cell immunotherapy sector experienced a significant rally in the afternoon, with Kaineng Health hitting a 20% limit up, and Jimin Health, Zhongyuan Qihe, and Nanjing Xinbai also previously reaching their limit up [1] - Sanyuan Gene saw an increase of over 10%, while Chengda Pharmaceutical and Sunshine Nuohe also followed the upward trend [1] - A recent research paper published in the journal Nature Biotechnology indicates that low-intensity ultrasound treatment can eliminate neurotoxic debris in the brains of mice induced with hemorrhagic stroke [1]

Market Overview - A-shares experienced a decline with over 4000 stocks falling; the power equipment and communication sectors led the drop, while financial and petrochemical sectors showed strength [1][2] - The total market turnover reached 1.27 trillion yuan, remaining stable compared to the previous day [2] Sector Performance - The power equipment sector saw significant declines, with stocks like Aster down 17% and Aero Energy nearly 12% [2][4] - Major stocks in the solar energy sector, including Tongwei Co. and Longi Green Energy, fell over 8% [4] - The financial sector performed well, with Agricultural Bank of China’s market cap surpassing 3 trillion yuan, marking a historical high [7][8] Stock Highlights - Agricultural Bank of China rose over 4%, while other major banks like China Life and China Pacific Insurance increased by over 2% [7][8] - The stock of Hezhong China recorded a 12-day streak with 11 limit-up days, despite being in a loss-making state, indicating potential irrational market behavior [10] Market Sentiment - There is a noticeable trend of speculative trading based on stock names, with several stocks experiencing rapid price increases despite no significant changes in their fundamentals [10]

Group 1: Company Developments - Zhongrui Co., Ltd. established a subsidiary, Guiyan Zun Wine Industry (Shanghai) Co., Ltd., focusing on high-quality sauce liquor from core production areas [2] - Zhejiang Dongri's main revenue comes from agricultural product wholesale and fresh food delivery services; its subsidiary Peianmei is advancing brain-computer interface technology with Capital Medical University [2] - Kunlongda is the first domestic company to list functional labor protection gloves [2] - China National Cereals, Oils and Foodstuffs Corporation (COFCO) Sugar's total operating volume is 3 million tons, accounting for 20% of national sugar consumption [2] - Jimo Wang is a leading men's pants brand in China [2] - Furi Co., Ltd. is the first company in China's home textile industry to go public, focusing on lithium battery electrolyte additives [2] Group 2: Industry Trends - China's largest shale oil production base, Changqing Oilfield, has a cumulative shale oil output exceeding 20 million tons [2] - The domestic aluminum price continues to rise as industry capacity approaches its limit [5] - The global lithium battery storage installation exceeded 170 GWh in the first three quarters of 2025, a year-on-year increase of 68% [6] - The third quarter saw significant growth in biodiesel exports [5] - The National Development and Reform Commission and the Energy Administration released guidelines to promote renewable energy consumption and regulation [3]

Core Viewpoint - The company, Jimin Health (603222), has stated that the number of shareholders at the end of each quarter will be disclosed in regular reports, and shareholders can request information for specific dates by providing proof of shareholding [1] Summary by Categories - **Shareholder Information Disclosure** - The company will disclose the number of shareholders at the end of each quarter in its periodic reports [1] - Shareholders wishing to obtain the number of shareholders for other specific dates must provide written documentation proving the type and quantity of shares held [1] - The company will verify the identity of shareholders before providing the requested information [1]

Group 1 - The A-share market opened higher but declined, with the medical sector showing volatility. The medical device ETF (562600) fell by 0.54% but has seen net inflows for 10 consecutive trading days, with stocks like Jimin Health, Yirui Technology, and Hualan Biological leading the gains [1] - Mindray Medical, the largest component stock, submitted an application for issuing H-shares and listing on the Hong Kong Stock Exchange on November 10, with Huatai International and JPMorgan as joint sponsors [1] - The Chinese pharmaceutical industry has completed the transition of growth drivers, with medical devices and supply chains gaining a strong position globally. The demand and payment sides are continuously driving new growth, supported by the aging population and stable growth in medical insurance revenue [1] Group 2 - The long-term positive trend in the medical device sector remains unchanged, with the medical device ETF (562600) providing a convenient way to invest in this area. The ETF tracks the CSI All-Share Medical Device Index, which includes 100 representative companies in medical devices, services, and information technology [2] - Investors can also consider the 华夏中证全指医疗器械ETF发起式联接A (021250) and 华夏中证全指医疗器械ETF发起式联接C (021251) for easier access to the medical device sector [2]